The Medicines Patent Pool and Unitaid respond to access efforts for COVID-19 treatments and technologies
The Board of the Medicines Patent Pool (MPP) has decided to temporarily expand its mandate to include any health technology that could contribute to the global response to COVID-19 and where licensing could facilitate innovation and access. Read MPP-Unitaid's joint statement
Affordable versions of hepatitis C medicine daclatasvir soon available in additional countries
Bristol-Myers Squibb has announced that the marketing authorisations for daclatasvir will be withdrawn or will be allowed to lapse in countries where the product no longer is routinely prescribed or where there are other therapeutic options available. This means that patients diagnosed with hepatitis C in additional countries will soon have access to generic versions of daclatasvir. Discover which countries are concerned by this news
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
We are now including some patented medicines being tested for the treatment of COVID-19.
Geneva, 20 May 2020 - MPP welcomes the adoption of resolution at the 73rd WHA that calls for intensification of efforts to control the COVID-19 pandemic, and for equitable access to and fair distribution of all essential health technologies and products to combat the novel coronavirus.
The resolution, proposed in the first-ever virtual WHA, was co-sponsored by more than 130 countries, and adopted by consensus. The assembly (18-19 May) witnessed interventions from ministers of health from almost every country in the world. All voices echoed the importance of solidarity and the mission of leaving no one behind, as we move forward in controlling this outbreak.
One of the key aspects of the resolution is to work collaboratively through “existing mechanisms for voluntary pooling and licensing of patents”. As the only existing patent pooling mechanism in the public health field, MPP looks forward to playing that role.
“It is critical to lay the groundwork for access while these treatments and vaccines are...
Geneva, 18 May 2020 - The COVID-19 crisis has drawn major international attention to the need to ensure access to new technologies that will likely play a central role in overcoming the pandemic. It is essential to prepare for access while some of these technologies relating to vaccines, diagnostics and treatments are still being developed, so that these become available and affordable as quickly and widely as possible.
Licensing under public health-oriented terms and patent pooling is a proven way for making patented health technologies rapidly available at affordable prices for all those in need. It is a strategy that has worked very well in HIV, where millions of people today are getting access to affordable new treatments shortly after they are developed. It’s the strategy that Medicines Patent Pool (MPP) has been implementing, with the support of Unitaid and together with our partners in industry, governments and civil society.
On March 31st, MPP announced the expansion of its mandate to include an...
Geneva, 4 May 2020 - The Medicines Patent Pool (MPP) welcomes the Coronavirus Global Response, where countries and organisations around the world are joining forces to accelerate the development, production and equitable access to COVID-19 vaccines, diagnostics and therapeutics.
The solidarity and generosity of countries is an exceptional show of commitment towards a coordinated global response to leave no one behind. “We know that all too often access to treatments and technologies in low- and middle-income countries lags behind. We cannot afford this time lag in the fight against COVID-19,” said Marie-Paule Kieny, Chair of the MPP Board. “Voluntary licensing, as provided through MPP, is a transparent, equitable and affordable way to supply medicines for whoever and wherever they are needed.”
MPP strongly supports the multilateral response put forth by the different Heads of States. We will assist Unitaid as it co-convenes the therapeutic partnership, and stand ready to engage, as needed, in all areas...
“We support the engagement of all relevant organizations, such as WHO, UNAIDS, Gavi, the Global Fund, and Unitaid and initiatives, including the recent expansion of the Medicines Patent Pool, in their work to improve access for all to safe, effective, quali...”
Unable to load twitter timeline, please allow cookie